DUX4 and facioscapulohumeral muscular dystrophy: Importantly, in a recent study, PAS-targeting PMOs delivered systemically reduced DUX4 and its targets, ameliorated pathology, and improved muscle function in the FLExDUX4 FSHD mouse model [67,68].